Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells

Abstract Background Challenges exist in the clinical treatment of luminal estrogen receptor α (ERα)-positive breast cancers (BCs) both to prevent resistance to endocrine therapy (ET) and to treat ET-resistant metastatic BCs (MBC). Therefore, we evaluated if kinases could be new targets for the treat...

Full description

Bibliographic Details
Main Authors: Sara Pescatori, Stefano Leone, Manuela Cipolletti, Stefania Bartoloni, Alessandra di Masi, Filippo Acconcia
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Breast Cancer
Estrogen Receptor α
17β-estradiol
4OH-tamoxifen
CHK1
CHK2
Online Access:https://doi.org/10.1186/s13046-022-02360-y

Internet

https://doi.org/10.1186/s13046-022-02360-y

Similar Items